HT047

HT047 is a long-acting recombinant human tissue plasminogen activator (rtPA) fusion protein developed by Huons for the treatment of acute ischemic stroke. The molecule is engineered using albumin fusion technology (HumaMax platform) to extend its circulating half-life compared to standard thrombolytic agents like alteplase. HT047 functions by binding to fibrin within a thrombus and catalyzing the conversion of plasminogen into plasmin. Plasmin then proteolytically degrades the fibrin matrix, leading to the dissolution of the blood clot and restoration of blood flow to ischemic brain tissue. The drug completed Phase II clinical evaluation in South Korea, but development was reportedly terminated in 2023 due to strategic business considerations.

Other names

recombinant human tissue plasminogen activatorrtPAlong-acting rtPArtPA-albumin fusion protein